# 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

> **NCT00293319** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 164 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **RADIATION:** iobenguane I 131

## Key facts

- **NCT ID:** NCT00293319
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2014-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293319, "131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00293319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*